Biogen Inc Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Biogen Inc Insights data

Headline Published Journalists
Showing 3 of 270+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 22 Sep 2021 Lorem
OIG investigation into accelerated approval unlikely to cause dramatic FDA overhaul despite controversy over Biogen’s Aduhelm 13 Aug 2021 William Newton
Biogen’s Aduhelm for Alzheimer's disease needs more safety data to alleviate concerns over ARIA side effect 11 Aug 2021 William Newton
Medicare’s National Coverage Determination could boost chances of limited Aduhelm coverage in Alzheimer's disease despite current backlash 30 Jul 2021 William Newton


Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.


Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships


Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.


Access more premium companies when you subscribe to Explorer